Comparative Study of the Mutant Prevention Concentrations of Moxifloxacin, Levofloxacin, and Gemifloxacin against Pneumococci

被引：9

作者：

Credito, Kim ^{[1
]}

Kosowska-Shick, Klaudia ^{[1
]}

McGhee, Pamela ^{[1
]}

Pankuch, Glenn A. ^{[1
]}

Appelbaum, Peter C. ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 02期

关键词：

STREPTOCOCCUS-PNEUMONIAE MUTANTS; SELECTION WINDOW HYPOTHESIS; RESISTANT MUTANTS; FLUOROQUINOLONES; SUSCEPTIBILITY; CIPROFLOXACIN; PHARMACODYNAMICS; PHARMACOKINETICS; GARENOXACIN; QUINOLONE;

D O I：

10.1128/AAC.01353-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We tested the propensity of three quinolones to select for resistant Streptococcus pneumoniae mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint (P < 0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC50) value (1 mu g/ml) within the susceptible range.

引用

页码：673 / 677

页数：5

共 27 条

[1] Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].

Allen, GP ;

Kaatz, GW ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614

[2] Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections [J].

Andes, D ;

Anon, J ;

Jacobs, MR ;

Craig, WA .

CLINICS IN LABORATORY MEDICINE, 2004, 24 (02) :477-+

[3] Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones [J].

Blondeau, J. M. ;

Blondeau, L. D. ;

Hesje, C. ;

Borsos, S. .

JOURNAL OF CHEMOTHERAPY, 2006, 18 (04) :366-372

[4] Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].

Blondeau, JM ;

Zhao, XL ;

Hansen, G ;

Drlica, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438

[5]

*CLIN LAB STAND I, 2009, M100S19 CLIN LAB STA

[6]

Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE, V7

[7] Re-evaluating current antibiotic therapy [J].

Craig, WA .

RESPIRATORY MEDICINE, 2001, 95 :S14-S21

[8] Changes in Fluoroquinolone-Resistant Streptococcus pneumoniae after 7-Valent Conjugate Vaccination, Spain [J].

de la Campa, Adela G. ;

Ardanuy, Carmen ;

Balsalobre, Luz ;

Perez-Trallero, Emilio ;

Marimon, Jose M. ;

Fenoll, Asuncion ;

Linares, Josefina .

EMERGING INFECTIOUS DISEASES, 2009, 15 (06) :905-911

[9] In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus [J].

Firsov, AA ;

Vostrov, SN ;

Lubenko, IY ;

Drlica, K ;

Portnoy, YA ;

Zinner, SH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1604-1613

[10] Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model [J].

Firsov, Alexander A. ;

Smirnova, Maria V. ;

Lubenko, Irene Yu. ;

Vostrov, Sergey N. ;

Portnoy, Yury A. ;

Zinner, Stephen H. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (06) :1185-1192

← 1 2 3 →